UCB Bepranemab shows mixed results in Alzheimer's phase 2a
UCB presented results from the phase 2a (TOGETHER) study of bepranemab (antibody targeting the mid-region of tau) in people living with prodromal to mild Alzheimer's disease (AD) during a late-breaker at the Clinical Trials on Alzheimer's Disease (CTAD) conference. The results showed a miss on the primary endpoint, but some signal on secondary endpoints and in sub-group analysis. With the candidate back with UCB from Genentech, the company is evaluating next steps in the development program. We considered this a moon-shot program, with <1% contribution to our SOTP. As such, we reiterate our € 173 TP and Accumulate rating.UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.